NVIDIA Partners with Healthcare Leaders to Revolutionize Drug Discovery and Patient Care through Advanced AI Solutions

NVIDIA announced partnerships to use AI in healthcare, enhancing drug discovery and genomic research, aiming to improve patient outcomes.

Quiver AI Summary

NVIDIA has announced new partnerships with healthcare leaders IQVIA, Illumina, Mayo Clinic, and Arc Institute at the J.P. Morgan Healthcare Conference, aiming to revolutionize the healthcare and life sciences sector valued at $10 trillion through AI technologies. These collaborations focus on accelerating drug discovery, enhancing genomic research, and improving healthcare services. NVIDIA's advanced AI solutions will be utilized to streamline clinical trials, facilitate drug development, and enhance patient care through robotics and AI-driven insights. The partners will integrate NVIDIA's AI tools with extensive healthcare data to expedite the discovery of treatments and enhance diagnostic capabilities, with a particular emphasis on making genomic analysis more accessible and efficient. The initiatives are expected to result in significant advances in medical innovation and patient outcomes worldwide.

Potential Positives

• NVIDIA is partnering with industry leaders such as IQVIA, Illumina, Mayo Clinic, and Arc Institute to enhance drug discovery and healthcare services through advanced AI technologies, positioning the company as a key player in the $10 trillion healthcare market.
• The announcement highlights NVIDIA's role in pioneering AI applications that could significantly improve patient outcomes and accelerate medical innovation, aligning with ongoing trends toward digitization in healthcare.
• Collaborations with organizations like IQVIA and Illumina leverage NVIDIA's AI Foundry services and computing platforms to create tailored solutions that address critical challenges in clinical trials, genomic analysis, and disease detection, enhancing NVIDIA’s technology use cases across the healthcare industry.
• The development of AI models and tools with Arc Institute aims to advance biomedical discoveries, further expanding NVIDIA's influence and capabilities within the life sciences research community.

Potential Negatives

• Forward-looking statements in the release indicate potential risks and uncertainties that could materially impact NVIDIA's projected outcomes in the healthcare sector.


• The mention of reliance on third-party manufacturers highlights a vulnerability that could disrupt NVIDIA's product availability and market performance.


• Implicitly, the release emphasizes fierce competition in the AI and healthcare technology markets, which could threaten NVIDIA's market share and profitability if unmet expectations arise.

FAQ

What new partnerships has NVIDIA announced for healthcare?

NVIDIA has partnered with IQVIA, Illumina, Mayo Clinic, and Arc Institute to enhance healthcare through AI and advanced computing.

How is NVIDIA using AI in drug discovery?

NVIDIA is developing AI models and agents to accelerate drug discovery and clinical trials, reducing operational burdens in healthcare.

What role does AI play in genomic research with Illumina?

Illumina collaborates with NVIDIA to optimize multiomics analysis software, enhancing genomic insights for drug discovery and research.

How will Mayo Clinic benefit from NVIDIA's technology?

Mayo Clinic will utilize NVIDIA's AI and robotics to improve digital pathology and accelerate diagnostics for cancer and complex conditions.

What is the focus of the Arc Institute's collaboration with NVIDIA?

The Arc Institute aims to develop AI models for biomedical discovery, advancing applications in drug discovery and synthetic biology.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$NVDA Congressional Stock Trading

Members of Congress have traded $NVDA stock 21 times in the past 6 months. Of those trades, 10 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $NVDA stock by members of Congress over the last 6 months:

• SENATOR SHELDON WHITEHOUSE sold up to $50,000 on 01/06.
• REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 4 times. They made 4 purchases worth up to $60,000 on 12/24, 11/25, 09/03, 08/21 and 0 sales.
• REPRESENTATIVE MORGAN MCGARVEY has traded it 5 times. They made 0 purchases and 5 sales worth up to $110,000 on 11/13.
• REPRESENTATIVE JOSH GOTTHEIMER has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 11/12, 10/17.
• REPRESENTATIVE JARED MOSKOWITZ purchased up to $15,000 on 11/08.
• REPRESENTATIVE PETE SESSIONS has traded it 3 times. They made 3 purchases worth up to $45,000 on 11/01, 09/16, 09/10 and 0 sales.
• REPRESENTATIVE THOMAS R. SUOZZI has traded it 3 times. They made 1 purchase worth up to $50,000 on 10/24 and 2 sales worth up to $65,000 on 10/24, 10/02.
• REPRESENTATIVE JOHN JAMES sold up to $15,000 on 09/04.
• REPRESENTATIVE NANCY PELOSI purchased up to $5,000,000 on 07/26.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$NVDA Insider Trading Activity

$NVDA insiders have traded $NVDA stock on the open market 256 times in the past 6 months. Of those trades, 0 have been purchases and 256 have been sales.

Here’s a breakdown of recent trading of $NVDA stock by insiders over the last 6 months:

• AJAY K PURI (EVP, Worldwide Field Ops) has traded it 6 times. They made 0 purchases and 6 sales, selling 36,695 shares.
• TENCH COXE has traded it 6 times. They made 0 purchases and 6 sales, selling 3,000,000 shares.
• COLETTE KRESS (EVP & Chief Financial Officer) has traded it 10 times. They made 0 purchases and 10 sales, selling 133,340 shares.
• DONALD F JR ROBERTSON (Principal Accounting Officer) has traded it 9 times. They made 0 purchases and 9 sales, selling 9,000 shares.
• JOHN DABIRI sold 716 shares.
• MARK A STEVENS has traded it 4 times. They made 0 purchases and 4 sales, selling 485,100 shares.
• JEN HSUN HUANG (President and CEO) has traded it 220 times. They made 0 purchases and 220 sales, selling 3,600,000 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$NVDA Hedge Fund Activity

We have seen 2,379 institutional investors add shares of $NVDA stock to their portfolio, and 1,774 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• GQG PARTNERS LLC removed 64,596,211 shares (-85.4%) from their portfolio in Q3 2024
• INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC removed 55,808,611 shares (-99.1%) from their portfolio in Q4 2024
• FMR LLC removed 46,189,661 shares (-4.4%) from their portfolio in Q3 2024
• BANK OF AMERICA CORP /DE/ added 39,169,586 shares (+19.0%) to their portfolio in Q3 2024
• PRICE T ROWE ASSOCIATES INC /MD/ removed 36,974,039 shares (-8.3%) from their portfolio in Q3 2024
• STATE STREET CORP removed 35,750,704 shares (-3.6%) from their portfolio in Q3 2024
• LEGAL & GENERAL GROUP PLC added 28,923,318 shares (+13.6%) to their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) --

J.P. Morgan Healthcare Conference

-- NVIDIA today announced new partnerships to transform the $10 trillion healthcare and life sciences industry by accelerating drug discovery, enhancing genomic research and pioneering advanced healthcare services with agentic and generative AI.

The convergence of AI, accelerated computing and biological data is turning healthcare into the largest technology industry. Healthcare leaders IQVIA, Illumina and


Mayo Clinic


, as well as Arc Institute, are using the latest NVIDIA technologies to develop solutions that will help advance human health.

These solutions include AI agents that can speed clinical trials by reducing administrative burden, AI models that learn from biology instruments to advance drug discovery and digital pathology, and physical AI robots for surgery, patient monitoring and operations. AI agents, AI instruments and AI robots will help address the $3 trillion of operations dedicated to supporting industry growth and create an AI factory opportunity in the hundreds of billions of dollars.

“AI offers an exceptional opportunity to advance healthcare and life sciences with tools that help providers detect diseases earlier and discover new treatments faster,” said Kimberly Powell, vice president of healthcare at NVIDIA. “The combination of NVIDIA’s AI and accelerated computing capabilities with the expertise of industry leaders is poised to usher in a new era of medical and biological innovation and improve patient outcomes worldwide.”

AI Foundry Services Boost Drug and Medical Device Development



IQVIA — a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries — is using the


NVIDIA AI Foundry


service to build custom foundation models on its more than 64 petabytes of information, coupled with its deep domain expertise. The company is also developing agentic AI solutions, outfitted with NVIDIA AI Enterprise software including


NVIDIA NIM


™ microservices and


NVIDIA Blueprints


, that can speed research, clinical development and access to new treatments. IQVIA has been leading in the responsible use of AI, ensuring that its AI-powered capabilities are grounded in privacy, regulatory compliance and patient safety.

“This represents a significant leap forward in how we apply AI to healthcare and life sciences,” said Bhavik Patel, president of commercial solutions at IQVIA. “We are excited to combine our industry-leading capabilities and a decade of experience in artificial intelligence with NVIDIA’s advanced AI technologies to build new solutions powered by AI agents that are trained on world-class healthcare information and optimized for life sciences workflows. This collaboration will advance our mission to help our clients accelerate innovation and treatments to market.”

Illumina and NVIDIA Supercharge Next Era of Genomic Breakthroughs



Illumina, a global leader in DNA sequencing and informatics technologies, is working with NVIDIA to unlock the next generation of genomics for drug discovery and human health.

This partnership will enable Illumina to use NVIDIA accelerated computing and AI toolsets for its multiomics analysis software and workflows. This will help make analysis of — and insights from — the human genome more accessible to researchers, pharmaceutical companies and other life sciences customers.

Illumina will offer DRAGEN analysis software on NVIDIA accelerated computing within the Illumina Connected Analytics platform. The integration aims to expand DRAGEN accessibility globally to wherever NVIDIA’s computing platform exists.

Over the last five years, single-cell and spatial genomics have revolutionized drug discovery by providing unprecedented insights into cell understanding. To further expand the genomics market and help enable breakthroughs in target identification, clinical development and biomarker discovery, NVIDIA and Illumina plan to collaborate to progress multiomics data analysis on the Illumina Connected Analytics platform, in addition to developing new biology foundation models.

The R&D community can more quickly and easily tap into rich genomic data by integrating


NVIDIA RAPIDS


™ accelerated data science software, included in the NVIDIA AI Enterprise software platform, with the


NVIDIA BioNeMo


™ platform’s generative AI models and fine-tuning capabilities for proprietary datasets, and


MONAI


for spatial cell imaging workflows. Illumina and NVIDIA will work to make these tools accessible on the Illumina Connected Analytics platform.

“Our ability to combine the power of AI with multiomics data is revolutionizing how we can understand disease,” said Steve Barnard, chief technology officer at Illumina. “By combining Illumina’s expertise in genomics data and analysis with NVIDIA’s powerful AI platforms, we aim to enable pharma and biotech companies to unlock their own multiomics data to uncover transformative insights and improve success rates in developing lifesaving therapies.”

Mayo Clinic’s AI-Powered Digital Pathology

Pathology, an essential modality clinicians use to diagnose and determine treatments for many types of cancer and other serious and complex health conditions, is a historically slow and manual process. Mayo Clinic Digital Pathology platform, built from autonomous robotic labs and advanced imaging technology, offers a rich and unique dataset of 20 million whole-slide images with 10 million associated patient records to enable the creation of foundation models.

Mayo Clinic and NVIDIA will massively accelerate the development of next-generation pathology foundation models. Mayo Clinic is planning to deploy newly available


NVIDIA DGX™ Blackwell systems


— which are based on the NVIDIA Blackwell architecture and offer 1.4TB of GPU memory per system, ideal for handling digital pathology whole-slide datasets — and NVIDIA’s healthcare imaging platform MONAI.

Mayo Clinic and NVIDIA are pioneering this work to serve as a cornerstone for future AI applications in drug discovery, and personalized diagnostics and treatments. The companies will continue to expand this collaboration with Mayo’s clinical and AI expertise and NVIDIA Cosmos Nemotron vision language models and NIM microservices to provide more personalized healthcare experiences, along with predictive and efficient treatment strategies.

Scaling Open Science Biology AI Models With Arc Institute

Arc Institute, a Palo Alto, California-based research organization operating at the intersection of biology and machine learning, is collaborating with NVIDIA to develop and share powerful AI models and tools that advance biomedical discovery.

Arc’s biology and machine learning researchers are working with NVIDIA’s engineers to scale the potential of foundation models for biology that can generalize across different modalities, like DNA, RNA and proteins, and advance applications for drug discovery, synthetic biology across multiple scales of complexity, disease and evolution research, and more.

As part of the collaboration, NVIDIA has provided Arc Institute with expertise in large-scale model development; the NVIDIA BioNeMo platform running on


NVIDIA DGX Cloud


for easy-to-use, optimized training; and NVIDIA NIM microservices and Blueprints.

About NVIDIA





NVIDIA


(NASDAQ: NVDA) is the world leader in accelerated computing.

For further information, contact:



Janette Ciborowski


Enterprise Communications


NVIDIA Corporation


+1-734-330-8817




jciborowski@nvidia.com

Certain statements in this press release including, but not limited to, statements as to: the benefits, impact, availability, and performance of NVIDIA’s products, services, and technologies, including NVIDIA AI Foundry, NVIDIA NIM microservices, NVIDIA Blueprints, NVIDIA RAPIDS, NVIDIA AI Enterprise software platform, NVIDIA BioNeMo, NVIDIA MONAI, NVIDIA DGX B200 systems, NVIDIA Blackwell architecture, and NVIDIA DGX Cloud; NVIDIA’s partnership and collaboration with third parties, and the benefit and impact thereof; third parties adopting NVIDIA’s products and technologies, the benefits and impact thereof, and the features and performance of their offerings; and the combination of NVIDIA’s AI and accelerated computing capabilities with the expertise of industry leaders being poised to usher in a new era of medical and biological innovation and improve patient outcomes worldwide are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners' products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems; as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company's website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Many of the products and features described herein remain in various stages and will be offered on a when-and-if-available basis. The statements above are not intended to be, and should not be interpreted as a commitment, promise, or legal obligation, and the development, release, and timing of any features or functionalities described for our products is subject to change and remains at the sole discretion of NVIDIA. NVIDIA will have no liability for failure to deliver or delay in the delivery of any of the products, features or functions set forth herein.

© 2025 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, BioNeMo, DGX, NVIDIA NIM and NVIDIA RAPIDS are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.

A photo accompanying this announcement is available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/e14dd92e-489e-4abe-9673-3b6ab795bd3f

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.